查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1250776

到 2028 年阿片類藥物使用障礙 (OUD) 市場預測——按藥物類別、分銷渠道、給藥途徑、年齡組和地區進行的全球分析

Opioid Use Disorder Market Forecasts to 2028 - Global Analysis By Drug Class, Distribution Channel, Route of Administration, Age group, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球阿片類藥物使用障礙 (OUD) 市場預計將在 2022 年佔 31.7 億美元，到 2028 年將達到 67.9 億美元。預計將以 13.5 的複合年增長率增長預測期內的百分比。

阿片類藥物是一類可以放鬆肌肉、緩解疼痛，還可以緩解壓力的藥物。 為了治療中度至重度疼痛，醫生通常會開一些藥物，例如氫可酮、羥考酮、可待因、芬太尼、美沙酮、嗎啡和其他處方阿片類藥物。 它被認為是一種大腦疾病，因為它涉及與動機、壓力、自我控制和決策相關的大腦迴路的功能變化，這些變化在停止吸毒後很長時間內仍會持續存在。

市場動態：

驅動程序

對支持政府和非政府組織擴張的興趣增加

政府和非政府組織越來越多地參與提高對阿片類藥物過量及其相關後果的認識，這也推動了該企業的擴張。 隨著阿片類藥物成癮的激增，一些團體正在加緊努力解決這個問題。 許多國家正在加緊努力幫助患者並減少阿片類藥物依賴的影響。 例如，衛生與公共服務部 (HHS) 已宣布資助藥物濫用治療和預防計劃，以改善阿片類藥物使用障礙的藥物輔助治療的可及性並遏制處方藥濫用。 預計類似計劃將鼓勵更多有阿片類藥物相關問題的人尋求治療。

抑製劑：

OUD藥物的副作用

由於用於治療阿片類藥物成癮的藥物的不利影響，市場預計在預測期內將面臨挑戰。 這些藥物經常引起肌肉疼痛、噁心、嘔吐、腹瀉、骨骼和關節疼痛、呼吸系統問題、膀胱疼痛、便秘和腹部絞痛。 此外，在藥物反應的極端情況下，人們可能會出現抑鬱和其他心理問題。 由於這些藥物存在的危險，美國食品和藥物管理局已經發出警告，這對這類藥物產生了負面影響，並導致減少用於此類治療的藥物的使用。

機會

越來越關注丁丙諾啡貼劑

最近，市場上觀察到對丁丙諾啡貼劑治療的需求不斷增加。 這些貼劑被認為是治療阿片類藥物使用障礙的有效藥物。 與傳統的自我給藥相比，透皮貼劑具有許多優勢，包括更簡單的藥物輸送機制和更少的疼痛。 對於需要 24/7 全天候阿片類藥物治療的阿片類藥物使用障礙患者，透皮貼劑也可能是一種有效的替代方案。 此外，在預測期內，越來越多的新患者預計將促進全球阿片類藥物使用障礙 (OUD) 市場的增長。

威脅

效應器戒斷綜合徵

戒斷綜合徵是在停止反復接觸藥物刺激後發展起來的，與依賴性有關。 應警告患者在不先減少劑量的情況下不要停止長期使用阿片類藥物。 作為物質使用障礙的一個子類，成癮可能會出現身體、心理或兩者兼而有之的症狀和體徵。 無論使用何種類型的阿片類藥物，戒斷症狀通常在依賴開始時開始出現。 阿片類藥物使用障礙的主要問題是戒斷症狀。 與美沙酮相比，海洛因戒斷症狀最早可能在最後一次服藥後 5 小時開始出現。 當戒斷症狀持續數天至數週時，稱為長期戒斷綜合徵。

COVID-19 的影響

冠狀病毒大流行對製藥行業產生了一系列積極和消極影響，具體取決於需求。 對醫院和診所等醫療機構的就診人數減少對某些藥物的需求產生了不利影響。 此外，一些政府已在全國范圍內發出嚴重警報，以努力減少感染冠狀病毒的人數。 結果，醫院之間的患者流動極差。 此外，醫療程序不必要的取消或延誤對市場增長產生了負面影響。 然而，在大流行期間，包括 Indivior PLC 在內的在阿片類藥物使用障礙市場運營的知名公司的產品收入全面下滑。 由於與 COVID-19 相關的中斷，例如鎖定和運輸問題，銷售額也直線下降。 因此，預計阿片類藥物使用障礙市場將消退。

丁丙諾啡細分市場預計在預測期內將成為最大的細分市場

估計丁丙諾啡細分市場將實現有利增長。 丁丙諾啡/諾洛酮舌下片、丁丙諾啡舌下片、商品名 Suboxone 最常被推薦用於治療 OUD。 由於其卓越的臨床表現，Suboxonefilm 已成為 OUD 市場上醫生最常開的處方藥。 該藥物的高接受度可能歸因於許多變量，包括高處方覆蓋率、高成癮控制、低濫用可能性和最小的副作用。你可以

在預測期內，腸外藥物領域有望呈現最高複合年增長率

由於各種劑量的 OUD 療法以腸胃外給藥形式的可用性，在預測期內，腸胃外給藥部分預計將以最快的複合年增長率增長。 因此，這種給藥方法繼續主導著全球市場。

市場份額最高的地區

由於公眾對 OUD 的認識不斷提高，預計亞太地區在預測期內將佔據最大的市場份額。 此外，該地區的高患者人數和不斷增長的醫療保健支出預計將推動該地區的市場增長。

複合年增長率最高的地區：

預計北美在預測期內的複合年增長率最高。 北美市場份額最高的主要驅動因素之一是美國和加拿大的阿片類藥物流行病，許多政府舉措都已到位。 例如，美國政府發起了一場打擊阿片類藥物成癮的公眾意識運動。 較新的藥物，如 Braeburn 的 CAM-2038-每月定期注射的附加丁丙諾啡皮下製劑，預計也將在整個預測年度進入美國市場。

主要發展：

2022 年 3 月，Collegium Pharmaceutical, Inc. 宣布已完成對 BioDelivery Sciences International Inc. 的收購。

2020 年 6 月，Titan Pharmaceuticals, Inc. 與 Indegene 建立合作夥伴關係，在美國建立多渠道數字營銷計劃，以進一步增強其向阿片類藥物成癮者提供 Probuphine 植入物 2016 的能力。.

2021 年 2 月，Orexo AB 宣布與 ApexB.io 和 Magellan Rx Management 合作，進一步研究 Modia 的使用。 該產品是專為患有阿片類藥物使用障礙的患者設計的數字療法。

2020 年 12 月，Orexo AB 與 Accord Healthcare 就 ZUBSOLV 和納洛酮舌下片在歐洲的商業化簽訂了獨家協議。

2019 年 2 月，雷迪博士實驗室宣佈在一項專利訴訟中獲得有利判決後重新推出丁丙諾啡和納洛酮舌下薄膜。

這份報告提供了什麼

  • 區域和國家級細分市場的市場份額評估
  • 向新進入者提出戰略建議
  • 2020、2021、2022、2025 和 2028 年的綜合市場數據
  • 市場驅動因素（市場趨勢、制約因素、機遇、威脅、挑戰、投資機會/建議等）
  • 根據市場預測在關鍵業務領域提出戰略建議
  • 競爭格局和趨勢
  • 公司簡介，包括詳細的戰略、財務狀況和近期發展
  • 供應鏈趨勢反映了最新的技術進步。

提供免費定制

購買此報告的客戶將免費獲得以下定制之一。

  • 公司簡介
    • 對其他市場參與者（最多 3 個）進行全面分析
    • 主要參與者的 SWOT 分析（最多 3 人）
  • 區域細分
    • 應客戶要求提供主要國家/地區的市場估算、預測和復合年增長率（注意：通過可行性檢查）
  • 競爭基準
    • 根據產品組合、地域分佈和戰略聯盟對主要參與者進行基準測試

內容

第 1 章執行摘要

第二章前言

  • 概覽
  • 利益相關者
  • 調查範圍
  • 調查方法
    • 數據挖掘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 調查來源
    • 主要研究信息來源
    • 二手研究資源
    • 假設

第三章市場趨勢分析

  • 司機
  • 約束因素
  • 機會
  • 威脅
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第 5 章全球阿片類藥物使用障礙 (OUD) 市場：按藥物類別分類

  • 美沙酮
  • 納曲酮
  • 丁丙諾啡
    • 布納維爾
    • 子加載
    • 薩博森
    • Zubsolve

第 6 章。全球阿片類藥物使用障礙 (OUD) 市場：按分銷渠道

  • 零售藥店和商店
  • 醫院藥房
  • 在線藥店

第 7 章。全球阿片類藥物使用障礙 (OUD) 市場：按給藥途徑

  • 腸外
  • 口語

第 8 章。全球阿片類藥物使用障礙 (OUD) 市場：按年齡組分類

  • 19-39歲
  • 40-59
  • 60 歲以上

第 9 章。全球阿片類藥物使用障礙 (OUD) 市場：按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 意大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 新西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 卡塔爾
    • 南非
    • 其他中東地區

第10章主要發展

  • 合同、夥伴關係、協作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章公司簡介

  • Alkermes
  • Titan Pharmaceuticals, Inc
  • Hikma Pharmaceuticals PLC
  • Indivior PLC
  • Mallinckrodt Pharmaceuticals
  • Camurus
  • Orexo AB
  • Viatris Inc
  • BioDelivery Sciences International Inc.
  • Teva Pharmaceuticals Usa, Inc
  • Mylan
  • Azanta
  • Braeburn
  • Chiesi Pharmaceuticals
  • DiaMo Narcotics
  • MaynePharma Group
  • Knight Therapeutics
  • Dr. Reddy's Laboratories
  • Collegium Pharmaceutical, Inc
  • Buvidal
Product Code: SMRC22653

According to Stratistics MRC, the Global Opioid Use Disorder (OUD) Market is accounted for $3.17 billion in 2022 and is expected to reach $6.79 billion by 2028 growing at a CAGR of 13.5% during the forecast period. Opioids are a class of medications that also relax muscles, lessen pain, and ease stress. To treat moderate to severe pain, doctors often prescribe drugs like hydrocodone, oxycodone, codeine, fentanyl, methadone, morphine, and other prescription opioids. It involves functional alterations to brain circuits associated to motivation, stress, self-control, and decision-making, and because those changes may persist for a long time after drug use has stopped, it is recognised as a brain condition.

Market Dynamics:

Driver:

Growing focus of government & non-government institutions to support expansion

The expansion of the business is being fuelled in part by the growing involvement of governmental and non-governmental organisations in raising awareness of opioid overdose and associated consequences. Several groups have expanded their efforts to combat the issue as a result of the sharp rise in the number of opioid addicts. In order to help patients and decrease the effects of opioid dependence, many countries have increased their efforts. For instance, Health and Human Services (HHS) announced financing for substance use treatment and prevention programmes in order to increase access to medication-assisted treatment for opioid use disorder and curb prescription drug abuse. It is predicted that similar programmes would motivate more people with opioid-related problems to seek treatment.

Restraint:

Adverse effects of OUD drugs

The market is expected to experience challenges throughout the forecast period due to the negative effects of the medications used to treat opioid addiction. These medications frequently cause muscle aches, nausea, vomiting, diarrhoea, bone or joint pain, respiratory problems, bladder pain, constipation, and cramping in the abdomen. In addition, in extreme instances of a medication reaction, the patient may also experience depression and other psychological issues. The U.S. FDA issued a warning due to the hazards involved with these medications, which has a negative effect on the drug class and decreases the use of medications for this type of treatment.

Opportunity:

Increasing consideration of buprenorphine patches

An increase in demand for buprenorphine patch treatments has lately been observed in the market. These patches are regarded as an effective medication for the treatment of opioid use disorders. Transdermal patches have a number of traditional, self-administered benefits, including an easier drug administration mechanism and less pain. Also, these transdermal patches might be a viable substitute for patients who need 24/7 opioid medication for opioid use disorder. Also, it is predicted that during the forecast period, a growing number of new patients will contribute to the growth of the global market for opioid use disorder (OUD).

Threat:

Effects withdrawal syndrome

Withdrawal syndrome, which develops when repeated exposure to a pharmaceutical stimulus is stopped, is linked to dependency. Patients should be warned not to stop using long-term opioids without first lowering their dosage. Substance use disorder's subcategory of dependency can show physical, psychological, or both signs and symptoms. Regardless of the type of opioid used, withdrawal symptoms usually begin around the time of dependence. The main issue with opioid use disorder is withdrawal. When compared to methadone, withdrawal from heroin might start as quickly as five hours following the last dose. Withdrawal symptoms that last for days or weeks are referred to as prolonged abstinence syndrome.

Covid-19 Impact

Due to demand, the coronavirus pandemic has a variety of effects on the pharmaceutical business, ranging from favourable to unfavourable. Because fewer people are visiting healthcare institutions like hospitals and clinics, there has been a detrimental effect on the demand for some medications. Furthermore, a handful of governments have implemented a rigorous nationwide lockdown in an effort to reduce the number of coronavirus cases. This has caused the flow of patients between hospital settings to drastically decrease. Moreover, the cancellation or delay of unnecessary medical treatments has had a detrimental effect on market expansion. However, throughout the pandemic, well-known companies operating in the market for opioid use disorders, including Indivior PLC, saw a general reduction in their product revenues. As a result of COVID-19-related disruptions including lockdowns, transportation problems, and others, sales have fallen down quickly. Thus, it is anticipated that the market for opioid use disorders will suffer a setback.

The buprenorphine segment is expected to be the largest during the forecast period

The buprenorphine segment is estimated to have a lucrative growth. The most frequently recommended medications for OUD are buprenorphine/naloxone sublingual pills, buprenorphine sublingual tablets, and brand-name Suboxone. Because to its outstanding clinical profile, Suboxone Film is the medication that doctors most frequently prescribe in the OUD market. The high acceptance of this medicine can be due to a number of variables, including its good formulary coverage, high efficacy in controlling addiction, low potential for abuse, and very minor adverse effects.

The parenteral segment is expected to have the highest CAGR during the forecast period

The parenteral segment is anticipated to witness the fastest CAGR growth during the forecast period, due to the availability of several OUD medications in parenteral form and a range of dosages. As a result, this method of drug administration continues to rule the world market.

Region with highest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to increasing awareness amongst the general population regarding OUD. Additionally, the substantial patient population base and the increasing healthcare spending in the region are likely to favour the growth of the market in the region.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period. One of the major drivers behind North America's largest market share is the opioid epidemic that has ravaged the United States and Canada due to the governments are implementing a number of initiatives. For instance, the American government started a public awareness campaign to fight opioid addiction. Throughout the course of the projected year, new medications are also anticipated to enter the U.S. market, including Braeburn's CAM-2038-additional buprenorphine subcutaneous formulation for regular monthly injection.

Key Players in the market

Some of the key players profiled in the Opioid Use Disorder (OUD) Market include Alkermes, Titan Pharmaceuticals, Inc, Hikma Pharmaceuticals PLC, Indivior PLC, Mallinckrodt Pharmaceuticals, Camurus, Orexo AB, Viatris Inc, BioDelivery Sciences International Inc., Teva Pharmaceuticals Usa, Inc, Mylan, Azanta, Braeburn, Chiesi Pharmaceuticals, DiaMo Narcotics, MaynePharma Group, Knight Therapeutics, Dr. Reddy's Laboratories, Collegium Pharmaceutical, Inc and Buvidal.

Key Developments:

In March 2022, Collegium Pharmaceutical, Inc. announced that it had completed the acquisition of BioDelivery Sciences International Inc.

In June 2020, Titan Pharmaceuticals, Inc. entered into a partnership with Indegene to establish a multichannel digital marketing program throughout the U.S. and further increase their competence in providing Probuphine implant 2016 for opioid addiction patients.

In February 2021, Orexo AB announced its collaboration with ApexB.io and Magellan Rx Management to further research the use of Modia. This product is a digital therapeutic designed for patients with Opioid Use Disorder.

In December 2020, Orexo AB entered into an exclusive agreement with Accord Healthcare for the commercialization of ZUBSOLV and naloxone sublingual tablets in Europe.

In February 2019, Dr. Reddy's Laboratories announced the re-launch of its buprenorphine and naloxone sublingual film after the company received a favourable ruling in patent litigation.

Drug Classes Covered:

  • Methadone
  • Naltrexone
  • Buprenorphine

Distribution Channels Covered:

  • Retail Pharmacies & Stores
  • Hospitals Pharmacies
  • Online Pharmacies

Route of Administrations Covered:

  • Parenteral
  • Oral

Age groups Covered:

  • 19 to 39
  • 40 to 59
  • Age 60 and over

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Opioid Use Disorder (OUD) Market, By Drug Class

  • 5.1 Introduction
  • 5.2 Methadone
  • 5.3 Naltrexone
  • 5.4 Buprenorphine
    • 5.4.1 Bunavail
    • 5.4.2 Sublocade
    • 5.4.3 Suboxone
    • 5.4.4 Zubsolv

6 Global Opioid Use Disorder (OUD) Market, By Distribution Channel

  • 6.1 Introduction
  • 6.2 Retail Pharmacies & Stores
  • 6.3 Hospitals Pharmacies
  • 6.4 Online Pharmacies

7 Global Opioid Use Disorder (OUD) Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Parenteral
  • 7.3 Oral

8 Global Opioid Use Disorder (OUD) Market, By Age group

  • 8.1 Introduction
  • 8.2 19 to 39
  • 8.3 40 to 59
  • 8.4 Age 60 and over

9 Global Opioid Use Disorder (OUD) Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Alkermes
  • 11.2 Titan Pharmaceuticals, Inc
  • 11.3 Hikma Pharmaceuticals PLC
  • 11.4 Indivior PLC
  • 11.5 Mallinckrodt Pharmaceuticals
  • 11.6 Camurus
  • 11.7 Orexo AB
  • 11.8 Viatris Inc
  • 11.9 BioDelivery Sciences International Inc.
  • 11.10 Teva Pharmaceuticals Usa, Inc
  • 11.11 Mylan
  • 11.12 Azanta
  • 11.13 Braeburn
  • 11.14 Chiesi Pharmaceuticals
  • 11.15 DiaMo Narcotics
  • 11.16 MaynePharma Group
  • 11.17 Knight Therapeutics
  • 11.18 Dr. Reddy's Laboratories
  • 11.19 Collegium Pharmaceutical, Inc
  • 11.20 Buvidal

List of Tables

  • Table 1 Global Opioid Use Disorder (OUD) Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Opioid Use Disorder (OUD) Market Outlook, By Drug Class (2020-2028) ($MN)
  • Table 3 Global Opioid Use Disorder (OUD) Market Outlook, By Methadone (2020-2028) ($MN)
  • Table 4 Global Opioid Use Disorder (OUD) Market Outlook, By Naltrexone (2020-2028) ($MN)
  • Table 5 Global Opioid Use Disorder (OUD) Market Outlook, By Buprenorphine (2020-2028) ($MN)
  • Table 6 Global Opioid Use Disorder (OUD) Market Outlook, By Bunavail (2020-2028) ($MN)
  • Table 7 Global Opioid Use Disorder (OUD) Market Outlook, By Sublocade (2020-2028) ($MN)
  • Table 8 Global Opioid Use Disorder (OUD) Market Outlook, By Suboxone (2020-2028) ($MN)
  • Table 9 Global Opioid Use Disorder (OUD) Market Outlook, By Zubsolv (2020-2028) ($MN)
  • Table 10 Global Opioid Use Disorder (OUD) Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 11 Global Opioid Use Disorder (OUD) Market Outlook, By Retail Pharmacies & Stores (2020-2028) ($MN)
  • Table 12 Global Opioid Use Disorder (OUD) Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
  • Table 13 Global Opioid Use Disorder (OUD) Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 14 Global Opioid Use Disorder (OUD) Market Outlook, By Route of Administration (2020-2028) ($MN)
  • Table 15 Global Opioid Use Disorder (OUD) Market Outlook, By Parenteral (2020-2028) ($MN)
  • Table 16 Global Opioid Use Disorder (OUD) Market Outlook, By Oral (2020-2028) ($MN)
  • Table 17 Global Opioid Use Disorder (OUD) Market Outlook, By Age group (2020-2028) ($MN)
  • Table 18 Global Opioid Use Disorder (OUD) Market Outlook, By 19 to 39 (2020-2028) ($MN)
  • Table 19 Global Opioid Use Disorder (OUD) Market Outlook, By 40 to 59 (2020-2028) ($MN)
  • Table 20 Global Opioid Use Disorder (OUD) Market Outlook, By Age 60 and over (2020-2028) ($MN)
  • Table 21 North America Opioid Use Disorder (OUD) Market Outlook, By Country (2020-2028) ($MN)
  • Table 22 North America Opioid Use Disorder (OUD) Market Outlook, By Drug Class (2020-2028) ($MN)
  • Table 23 North America Opioid Use Disorder (OUD) Market Outlook, By Methadone (2020-2028) ($MN)
  • Table 24 North America Opioid Use Disorder (OUD) Market Outlook, By Naltrexone (2020-2028) ($MN)
  • Table 25 North America Opioid Use Disorder (OUD) Market Outlook, By Buprenorphine (2020-2028) ($MN)
  • Table 26 North America Opioid Use Disorder (OUD) Market Outlook, By Bunavail (2020-2028) ($MN)
  • Table 27 North America Opioid Use Disorder (OUD) Market Outlook, By Sublocade (2020-2028) ($MN)
  • Table 28 North America Opioid Use Disorder (OUD) Market Outlook, By Suboxone (2020-2028) ($MN)
  • Table 29 North America Opioid Use Disorder (OUD) Market Outlook, By Zubsolv (2020-2028) ($MN)
  • Table 30 North America Opioid Use Disorder (OUD) Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 31 North America Opioid Use Disorder (OUD) Market Outlook, By Retail Pharmacies & Stores (2020-2028) ($MN)
  • Table 32 North America Opioid Use Disorder (OUD) Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
  • Table 33 North America Opioid Use Disorder (OUD) Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 34 North America Opioid Use Disorder (OUD) Market Outlook, By Route of Administration (2020-2028) ($MN)
  • Table 35 North America Opioid Use Disorder (OUD) Market Outlook, By Parenteral (2020-2028) ($MN)
  • Table 36 North America Opioid Use Disorder (OUD) Market Outlook, By Oral (2020-2028) ($MN)
  • Table 37 North America Opioid Use Disorder (OUD) Market Outlook, By Age group (2020-2028) ($MN)
  • Table 38 North America Opioid Use Disorder (OUD) Market Outlook, By 19 to 39 (2020-2028) ($MN)
  • Table 39 North America Opioid Use Disorder (OUD) Market Outlook, By 40 to 59 (2020-2028) ($MN)
  • Table 40 North America Opioid Use Disorder (OUD) Market Outlook, By Age 60 and over (2020-2028) ($MN)
  • Table 41 Europe Opioid Use Disorder (OUD) Market Outlook, By Country (2020-2028) ($MN)
  • Table 42 Europe Opioid Use Disorder (OUD) Market Outlook, By Drug Class (2020-2028) ($MN)
  • Table 43 Europe Opioid Use Disorder (OUD) Market Outlook, By Methadone (2020-2028) ($MN)
  • Table 44 Europe Opioid Use Disorder (OUD) Market Outlook, By Naltrexone (2020-2028) ($MN)
  • Table 45 Europe Opioid Use Disorder (OUD) Market Outlook, By Buprenorphine (2020-2028) ($MN)
  • Table 46 Europe Opioid Use Disorder (OUD) Market Outlook, By Bunavail (2020-2028) ($MN)
  • Table 47 Europe Opioid Use Disorder (OUD) Market Outlook, By Sublocade (2020-2028) ($MN)
  • Table 48 Europe Opioid Use Disorder (OUD) Market Outlook, By Suboxone (2020-2028) ($MN)
  • Table 49 Europe Opioid Use Disorder (OUD) Market Outlook, By Zubsolv (2020-2028) ($MN)
  • Table 50 Europe Opioid Use Disorder (OUD) Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 51 Europe Opioid Use Disorder (OUD) Market Outlook, By Retail Pharmacies & Stores (2020-2028) ($MN)
  • Table 52 Europe Opioid Use Disorder (OUD) Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
  • Table 53 Europe Opioid Use Disorder (OUD) Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 54 Europe Opioid Use Disorder (OUD) Market Outlook, By Route of Administration (2020-2028) ($MN)
  • Table 55 Europe Opioid Use Disorder (OUD) Market Outlook, By Parenteral (2020-2028) ($MN)
  • Table 56 Europe Opioid Use Disorder (OUD) Market Outlook, By Oral (2020-2028) ($MN)
  • Table 57 Europe Opioid Use Disorder (OUD) Market Outlook, By Age group (2020-2028) ($MN)
  • Table 58 Europe Opioid Use Disorder (OUD) Market Outlook, By 19 to 39 (2020-2028) ($MN)
  • Table 59 Europe Opioid Use Disorder (OUD) Market Outlook, By 40 to 59 (2020-2028) ($MN)
  • Table 60 Europe Opioid Use Disorder (OUD) Market Outlook, By Age 60 and over (2020-2028) ($MN)
  • Table 61 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Country (2020-2028) ($MN)
  • Table 62 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Drug Class (2020-2028) ($MN)
  • Table 63 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Methadone (2020-2028) ($MN)
  • Table 64 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Naltrexone (2020-2028) ($MN)
  • Table 65 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Buprenorphine (2020-2028) ($MN)
  • Table 66 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Bunavail (2020-2028) ($MN)
  • Table 67 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Sublocade (2020-2028) ($MN)
  • Table 68 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Suboxone (2020-2028) ($MN)
  • Table 69 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Zubsolv (2020-2028) ($MN)
  • Table 70 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 71 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Retail Pharmacies & Stores (2020-2028) ($MN)
  • Table 72 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
  • Table 73 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 74 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Route of Administration (2020-2028) ($MN)
  • Table 75 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Parenteral (2020-2028) ($MN)
  • Table 76 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Oral (2020-2028) ($MN)
  • Table 77 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Age group (2020-2028) ($MN)
  • Table 78 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By 19 to 39 (2020-2028) ($MN)
  • Table 79 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By 40 to 59 (2020-2028) ($MN)
  • Table 80 Asia Pacific Opioid Use Disorder (OUD) Market Outlook, By Age 60 and over (2020-2028) ($MN)
  • Table 81 South America Opioid Use Disorder (OUD) Market Outlook, By Country (2020-2028) ($MN)
  • Table 82 South America Opioid Use Disorder (OUD) Market Outlook, By Drug Class (2020-2028) ($MN)
  • Table 83 South America Opioid Use Disorder (OUD) Market Outlook, By Methadone (2020-2028) ($MN)
  • Table 84 South America Opioid Use Disorder (OUD) Market Outlook, By Naltrexone (2020-2028) ($MN)
  • Table 85 South America Opioid Use Disorder (OUD) Market Outlook, By Buprenorphine (2020-2028) ($MN)
  • Table 86 South America Opioid Use Disorder (OUD) Market Outlook, By Bunavail (2020-2028) ($MN)
  • Table 87 South America Opioid Use Disorder (OUD) Market Outlook, By Sublocade (2020-2028) ($MN)
  • Table 88 South America Opioid Use Disorder (OUD) Market Outlook, By Suboxone (2020-2028) ($MN)
  • Table 89 South America Opioid Use Disorder (OUD) Market Outlook, By Zubsolv (2020-2028) ($MN)
  • Table 90 South America Opioid Use Disorder (OUD) Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 91 South America Opioid Use Disorder (OUD) Market Outlook, By Retail Pharmacies & Stores (2020-2028) ($MN)
  • Table 92 South America Opioid Use Disorder (OUD) Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
  • Table 93 South America Opioid Use Disorder (OUD) Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 94 South America Opioid Use Disorder (OUD) Market Outlook, By Route of Administration (2020-2028) ($MN)
  • Table 95 South America Opioid Use Disorder (OUD) Market Outlook, By Parenteral (2020-2028) ($MN)
  • Table 96 South America Opioid Use Disorder (OUD) Market Outlook, By Oral (2020-2028) ($MN)
  • Table 97 South America Opioid Use Disorder (OUD) Market Outlook, By Age group (2020-2028) ($MN)
  • Table 98 South America Opioid Use Disorder (OUD) Market Outlook, By 19 to 39 (2020-2028) ($MN)
  • Table 99 South America Opioid Use Disorder (OUD) Market Outlook, By 40 to 59 (2020-2028) ($MN)
  • Table 100 South America Opioid Use Disorder (OUD) Market Outlook, By Age 60 and over (2020-2028) ($MN)
  • Table 101 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Country (2020-2028) ($MN)
  • Table 102 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Drug Class (2020-2028) ($MN)
  • Table 103 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Methadone (2020-2028) ($MN)
  • Table 104 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Naltrexone (2020-2028) ($MN)
  • Table 105 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Buprenorphine (2020-2028) ($MN)
  • Table 106 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Bunavail (2020-2028) ($MN)
  • Table 107 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Sublocade (2020-2028) ($MN)
  • Table 108 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Suboxone (2020-2028) ($MN)
  • Table 109 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Zubsolv (2020-2028) ($MN)
  • Table 110 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 111 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Retail Pharmacies & Stores (2020-2028) ($MN)
  • Table 112 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Hospitals Pharmacies (2020-2028) ($MN)
  • Table 113 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 114 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Route of Administration (2020-2028) ($MN)
  • Table 115 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Parenteral (2020-2028) ($MN)
  • Table 116 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Oral (2020-2028) ($MN)
  • Table 117 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Age group (2020-2028) ($MN)
  • Table 118 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By 19 to 39 (2020-2028) ($MN)
  • Table 119 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By 40 to 59 (2020-2028) ($MN)
  • Table 120 Middle East & Africa Opioid Use Disorder (OUD) Market Outlook, By Age 60 and over (2020-2028) ($MN)